Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

 Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

Shots:

  • Tessa to conduct a P-Ib/II trial assessing Tessa’s human papillomavirus-specific T cell (HPVST) therapy or TT12 with Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer
  • The P-Ib/II trial will be initiated in the US, Singapore, South Korea. Additionally, Tessa’s TT12 and an anti PD-1 therapy is being evaluated in P-I for patients with relapsed HPV-associated cancers, resulted in well-tolerated and minimal toxicity results in the US
  • Tessa’s TT12 is an autologous cell therapy based on HPVSTs targeting HPV 16/18 antigens and genetically modified with a decoy TGF-β receptor. Keytruda (pembrolizumab) is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2

Click here to read full press release/ article | Ref: Tessa Therapeutics | Image: WSJ

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post